Summary

• Over 15 years of experience in downstream process development for diverse molecule modalities.
• Broad expertise in chromatography, ultrafiltration/diafiltration, clarification, and analytical support.
• Proven success in process optimization, scale-up, risk assessment (FMEA), and tech transfer to manufacturing.
• Extensive collaboration with cross-functional teams and external CMOs/CDMOs.
• Demonstrated leadership, project management, and regulatory support experience.

Technical Skills

• Hands-on with AKTA systems, diverse chromatography modes, UF/DF, dialysis, and high-throughput screening.
• Expertise in clarification processes, analytical methods (HPLC, SDS PAGE), and endotoxin testing.
• Familiar with upstream processes, oligonucleotide synthesis, and antibody-drug conjugation techniques.

Work Experience

Editas Medicine Inc., Cambridge, MA

Associate Director (July 2024 – Present)
Senior Manager (May 2021 – July 2024)

• Led downstream purification development for Cas12a enzyme and AAV vectors.
• Directed FMEA risk assessments, DOE studies, and technology transfers to CMOs.
• Supported IND filings, authored technical documentation, and participated in regulatory meetings.

Takeda Pharmaceuticals, Lexington, MA

Senior Engineer (March 2018 – May 2021)

• Improved purification yield by 25% through 2nd-gen downstream development for enzyme therapies.
• Led technical cross-functional teams and managed CDMO collaboration for humabody programs.

Biogen Inc., Cambridge, MA

Associate Scientist III (Feb 2016 – Mar 2018)
Associate Scientist II (Dec 2012 – Feb 2016)

• Developed aqueous-based ASO purification process with improved purity and integrated it in manufacturing.
• Contributed to Biogen’s late-stage clinical manufacturing strategy and ASO process scale-up.